Abbreviations: ABCL = aggressive B-cell lymphoma; aGvHD = acute GvHD; cGvHD = chronic GvHD; ECOG = Eastern Cooperative Oncology Group performance status; IBCL = indolent B-cell lymphoma; LDH = lactate dehydrogenase; MCL = mantle cell lymphoma; PTCL = peripheral T-cell lymphoma; SCT = stem cell transplantation; ULN = upper limit of normal range. For PTCL patients anaplastic lymphoma kinase (ALK) status was not known in most cases due to the long-term character of this retrospective study.
Engraftment was defined as reaching neutrophil leukocytes of 0.5 × 10 9 /L and platelets of 50 × 10 9 /L. Median neutrophil and platelet engraftment was observed on days 16 (range 10-24) and 14 (range 7-28), respectively. Febrile neutropenia was seen in 57.3% of patients, 72.6% of which had documented infections. Grading of GvHD was performed using standard criteria; 7 patients surviving 100 days following transplantation were evaluable for chronic GvHD (cGvHD). Acute GvHD (aGvHD) grade I-IV occurred in 46.1% of patients and cGvHD developed in 23.5% of cases (Table 1) .
Median overall survival (OS) of the entire population was 13 months, with a 95% confidence interval (CI) of 7-74 months. Median follow-up was 5.5 years (95% CI 3.3-8.0 years). After 10 years the probability of OS was 29.4%. Of note, almost half of all deaths occurred within the first 12 months following transplantation.
Although age did not significantly influence OS or PFS, there was a tendency for higher CIR (P = 0.07) but lower NRM (P = 0.10) in patients aged above 55 years compared to younger patients. There was a 5-year survival benefit for patients transplanted in CR compared with those in PR and non-responders (OS 53.6% vs 39.5% vs 27.3%). However, results failed to show a significant difference after 10 years. OS did not significantly differ between patients transplanted from a related donor compared to an unrelated donor, with a 10-year survival of 31.8% and 26.3%, respectively. Although there was a better 5-year OS (44.9 vs 28.0%) and PFS (42.3 vs 28.2%) for patients who received a RIC therapy compared to patients with MAC regime, follow-up failed to show a statistical significant benefit.
Different histologies (MCL, ABCL, IBCL, PTCL) were analyzed for their impact on patient outcome. Significant differences were seen in OS (P = 0.04) and PFS (P = 0.01). The PTCL cohort had the best 10-year OS among all groups (54.2%). The worst survival was seen for ABCL patients with a 10-year OS of 15.6% (Figure 1) . Multivariable testing demonstrated an OS benefit for patients with PTCL. The mortality risk was fourfold higher in patients with ABCL (HR 4.6, P = 0.002, 95% CI 1.72-12.12). Survival in the PTCL cohort trended to be better compared to IBCL and MCL patients (HR 1.6, P = 0.42, 95% CI 0.51-5.07; HR 1.6, P = 0.45, 95% CI 0.47-5.52). Similar results were generated for PFS (ABCL: HR 5.0, P = 0.001, 95% CI 1.92-13.03; IBCL: HR 1.6, P = 0.38, 95% CI 0.54-5.04; MCL: HR 1.8, P = 0.33, 95% CI 0.55-5.92).
Various studies for different lymphoma entities have demonstrated that allogeneic transplantation may be an effective therapeutic option. 2, 3 In this study, we analyzed patients transplanted over a period of 15 years in a German university hospital setting, generating a 10-year follow-up. The observed OS of 39.9% after 5 years is comparable to other studies that have reported a 5-year survival between 24% 6 and 40%. 5 Retrospectively, the European Society for Blood and Marrow Transplantation data reported an OS at 4 years of 51.1% for low-grade NHL, 38.3% for intermediate-grade NHL and 42.1% for high-grade NHL. 3 Interestingly, after the first 5 years, the rate of events in our cohort decreased considerably, resulting in a 10-year OS of about 30%. In fact, the highest rate of deaths occurred within the first year following transplantation with a median OS of approximately 12 months. The incidence of acute GvHD was comparable to other reports, whereas the rate of chronic GvHD was lower. 5, 6 Of note, because of the retrospective design and long time of follow-up, it is possible that not all cases of GvHD were covered within our analyses.
Long-term data comparing the outcome of patients transplanted from a related or an unrelated donor in lymphoma population are scarce. Superior survival after unrelated transplantation has been reported in lymphoma patients undergoing RIC regimes. 8 In our cohort we did not find a difference in survival between patients according to their graft source. This confirms the results from a previously published study of 40 patients with a similar 3-year survival analyses for the related and unrelated donor group. 9 Within the past decade RIC regimens have been increasingly used as conditioning therapy prior to transplantation. A survival benefit for RIC has been shown in a retrospective study with 25 patients transplanted for relapsed or refractory NHL. 10 Our study did not find a long-term survival difference between RIC and MAC strategies. Although there was a better OS and PFS for the RIC group in the initial years following transplantation, this benefit was not sustained over time. Interestingly, patient age also did not significantly influence patient outcome. This may be related to the more toxic conditioning regimens used in the younger patients. The remission status is reported to have influence on patient prognosis. 11 In our study pre-transplant remission status influenced patients' outcome with a survival benefit for patients transplanted in CR at 5 years, but this failed to show statistical significance at the 10-year survival analysis. However, this observation may have been influenced by the small number of patients transplanted in CR.
The best survival rates were seen in patients with PTCL. Longterm disease control in PTCL after allogeneic transplantation has been reported in several studies. 4, 12, 13 Therefore the presence of an effective graft-versus-lymphoma effect has been proposed. 14, 15 Corresponding to these data we and others 6 demonstrate superior survival data for patients with PTCL in comparison to patients with BCL.
Although this study has limitations with regard to group sizes and retrospective design, it not only highlights the risks involved in directly following transplantation but also the potential longterm benefit for those surviving the first year. Despite novel therapeutic agents becoming available, it remains currently unclear how long these can control a relapsed disease condition. Further prospective studies are warranted to define which patients benefit best from an early allogeneic transplantation.
